Advanced prostate cancer experimental radioactive treatment—clinical trial decision making: patient experiences

Viljoen, Bianca ORCID: https://orcid.org/0000-0003-3412-2607 and Hofman, Michael S. and Chambers, Suzanne K. and Dunn, Jeff and Dhillon, Haryana and Davis, Ian D. and Ralph, Nicholas ORCID: https://orcid.org/0000-0002-7404-9996 (2021) Advanced prostate cancer experimental radioactive treatment—clinical trial decision making: patient experiences. BMJ Supportive and Palliative Care:002994. p. 1. ISSN 2045-435X


Abstract

Objectives: Nested qualitative studies within clinical trials provide the opportunity to better understand participant experiences of participation and identify areas where improved support is required. The purpose of this qualitative study is to describe the lived experiences of men with advanced prostate cancer participating in the TheraP trial; a randomised trial of 177Lu-PSMA-617 compared with cabazitaxel chemotherapy.

Methods: Fifteen men with advanced prostate cancer were recruited from the TheraP clinical trial and interviewed at three time points during the trial. Interviews were inductively analysed using thematic analysis. This research paper reports the results from the baseline interview at commencement of the trial, focusing specifically on participants’ enrolment experiences.

Results: Four themes were identified representing the lived experiences of men with advanced prostate cancer deciding to participate in the TheraP trial: (1) hoping to survive; (2) needing to feel informed; (3) choosing to participate and (4) being randomised. The process of deciding to enrol in a clinical trial is filled with indecision, emotional difficulties and focused on a desire to live.

Conclusions: For men with advanced prostate cancer, the experience of deciding to enrol in a clinical trial is principally driven by a desire to survive but interlinked with the need to make an informed decision as participants in this study expressed a preference for allocation to the experimental arm. Men seeking to enrol in clinical trials of new prostate cancer treatments would benefit from improved informational and decision support.


Statistics for USQ ePrint 43217
Statistics for this ePrint Item
Item Type: Article (Commonwealth Reporting Category C)
Refereed: Yes
Item Status: Live Archive
Additional Information: Published online: 9 August 2021. Permanent restricted access to ArticleFirst version, in accordance with the copyright policy of the publisher.
Faculty/School / Institute/Centre: Current - Faculty of Health, Engineering and Sciences - School of Nursing and Midwifery (1 Jan 2015 -)
Faculty/School / Institute/Centre: Current - Institute for Resilient Regions - Centre for Health Research (1 Apr 2020 -)
Date Deposited: 06 Sep 2021 02:56
Last Modified: 02 Nov 2021 01:51
Fields of Research (2008): 11 Medical and Health Sciences > 1103 Clinical Sciences > 110313 Nuclear Medicine
11 Medical and Health Sciences > 1117 Public Health and Health Services > 111799 Public Health and Health Services not elsewhere classified
11 Medical and Health Sciences > 1112 Oncology and Carcinogenesis > 111299 Oncology and Carcinogenesis not elsewhere classified
Fields of Research (2020): 32 BIOMEDICAL AND CLINICAL SCIENCES > 3211 Oncology and carcinogenesis > 321199 Oncology and carcinogenesis not elsewhere classified
42 HEALTH SCIENCES > 4203 Health services and systems > 420399 Health services and systems not elsewhere classified
32 BIOMEDICAL AND CLINICAL SCIENCES > 3202 Clinical sciences > 320215 Nuclear medicine
42 HEALTH SCIENCES > 4206 Public health > 420699 Public health not elsewhere classified
Funding Details:
Identification Number or DOI: https://doi.org/10.1136/bmjspcare-2021-002994
URI: http://eprints.usq.edu.au/id/eprint/43217

Actions (login required)

View Item Archive Repository Staff Only